Welcome to our dedicated page for Biolinerx SEC filings (Ticker: BLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLineRx Ltd. (BLRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on NASDAQ and the Tel Aviv Stock Exchange. BioLineRx files annual reports on Form 20‑F and frequent current reports on Form 6‑K, which together document its financial performance, clinical progress and material corporate events.
Recent Form 6‑K filings referenced by the company include quarterly financial results for periods ended March 31, June 30 and September 30, 2025. These reports incorporate condensed consolidated interim financial statements and operating and financial reviews, giving detail on revenues from APHEXDA royalties, research and development expenses, general and administrative costs, and the company’s cash position and runway guidance.
Filings also cover transactional and strategic developments. For example, a September 29, 2025 Form 6‑K describes the joint venture agreement with Hemispherian AS and the asset transfer of GLIX1‑related intellectual property into a newly created company. The filing outlines ownership percentages, funding commitments, governance arrangements and rights related to additional assets in Hemispherian’s pipeline.
Other 6‑K submissions attach press releases on topics such as the USPTO Notice of Allowance for GLIX1 patents, as well as shareholder meeting results, including approvals of director elections, changes to authorized share capital, compensation policy updates and auditor appointments.
On Stock Titan, these BLRX filings are supplemented by AI‑powered summaries that explain the key points of each document in plain language. Users can quickly understand the implications of lengthy 20‑F and 6‑K reports, track changes in financial metrics over time, and identify disclosures related to clinical trials, licensing agreements, equity issuances and corporate governance. The page also links to information on insider and major shareholder activity when reported on applicable SEC forms.
BioLineRx Ltd. filed a Form 6-K as a foreign private issuer for August 2025, reporting that it has released its financial results for the three and six months ended June 30, 2025. The submission includes a press release, unaudited condensed consolidated interim financial statements, and an operating and financial review for that period. These materials are incorporated by reference into all of the company’s effective registration statements under the Securities Act of 1933, meaning those registration statements now formally include the newly reported interim financial information.